Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Algernon update with Moreau on Wednesday ??

<< Previous

Bullboard Posts

Next >>

Comment by Raddnaron Oct 26, 2020 1:26pm

134 Views

Post# 31782138

RE:Algernon update with Moreau on Wednesday ??

Doubt it. Chris is adamant about not spilling the beans in any of his videos to be “fair” for investors.

we may have an update but not as big as 100% enrollment imo. I personally stopped watching these videos. A waste of time, just quick DND for new investors imo.

The key sign to look out for is a 15 minute trading halt.

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features